Top Page
ImExHS Limited
(Sydney:IME)
ImExHS Limited (IME) vs. iShares MSCI Australia ETF (EWA)
ImExHS Limited Business Overview & Revenue Model
ImExHS Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.35M | 26.57M | 19.67M | 17.12M | 13.37M | 10.91M |
| Gross Profit | 11.08M | 11.03M | 3.50M | 3.52M | 5.22M | 2.70M |
| EBITDA | -913.75K | 45.58K | -1.26M | -744.21K | -3.00M | -1.30M |
| Net Income | -4.11M | -2.63M | -4.19M | -3.04M | -4.70M | -3.62M |
Balance Sheet | ||||||
| Total Assets | 22.81M | 21.81M | 22.65M | 20.99M | 25.01M | 20.80M |
| Cash, Cash Equivalents and Short-Term Investments | 2.50M | 2.07M | 2.36M | 1.91M | 4.19M | 10.80M |
| Total Debt | 1.36M | 1.19M | 1.29M | 1.12M | 2.40M | 1.70M |
| Total Liabilities | 8.36M | 7.33M | 6.67M | 5.09M | 8.36M | 5.27M |
| Stockholders Equity | 14.45M | 14.47M | 15.98M | 15.90M | 16.65M | 15.54M |
Cash Flow | ||||||
| Free Cash Flow | -1.87M | -1.69M | 414.59K | -4.23M | -5.53M | -3.65M |
| Operating Cash Flow | -654.08K | -634.68K | 2.61M | -2.20M | -2.97M | -1.47M |
| Investing Cash Flow | -1.47M | -765.91K | -2.13M | -2.22M | -3.39M | -2.19M |
| Financing Cash Flow | 2.68M | 1.18M | -98.61K | 2.25M | -161.78K | 7.40M |
ImExHS Limited Technical Analysis
ImExHS Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$24.32M | -5.23 | -27.84% | ― | 6.77% | -8.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$58.12M | -9.39 | -13.83% | ― | 3.61% | -17.03% | |
48 Neutral | AU$22.32M | -12.37 | -17.05% | ― | 28.91% | -1050.00% | |
43 Neutral | AU$77.34M | -10.79 | ― | ― | ― | ― | |
42 Neutral | AU$53.30M | -5.84 | -8647.54% | ― | 25.98% | 22.10% |
ImExHS Limited Corporate Events
ImExHS Limited reported unaudited full-year 2025 results at the top end of its guidance, with revenue rising 10% to $29.0 million and underlying EBITDA more than tripling to $1.6 million, supported by a strong fourth quarter and a 16% increase in annualised recurring revenue to $34.8 million. Recurring revenue reached $28.5 million on a like-for-like basis, software revenue grew 25% in the fourth quarter excluding one-offs, and the company secured new and renewed enterprise contracts, public-sector tenders in Colombia and Mexico, and expanding partner programme contributions, while improving cash and cutting debt; management highlighted that these gains were achieved despite a volatile Colombian healthcare and FX environment, underscoring stronger execution and momentum into FY26.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.42 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
IMEXHS Limited has disclosed a change in the interests of director Douglas Flynn, detailing an internal restructuring of his shareholdings between direct and indirect holdings. Flynn disposed of 160,573 fully paid ordinary shares held directly, in an off-market sale to his superannuation vehicle, DR & LC Flynn Nominees Pty Limited
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has disclosed a change in director Damian Banks’ relevant interests in the company’s securities, reporting an internal restructuring of his holdings between direct and indirect ownership. Banks sold 80,287 fully paid ordinary shares off-market from his personal holding to Damisuper Pty Ltd, a superannuation fund vehicle for which he is a director and beneficiary, for approximately $31,312, leaving him with 37,356 options held directly and 1,997,836 ordinary shares held indirectly, without altering the overall economic exposure to the company.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has reported a change in the interests of director German Arango following the lapse of certain equity incentives. On 23 December 2025, 53,520 nil-price options held directly by Arango lapsed after vesting conditions were not met, reducing his holding of those specific options while leaving his remaining option grants and substantial direct and indirect shareholdings in the company unchanged. The disclosure underscores the conditional nature of the director’s incentive arrangements but does not alter his overall significant equity exposure to ImExHS.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has reported a change in the holdings of non-executive director Carlos Jaime Palacio, who maintains both direct and indirect interests in the company’s fully paid ordinary shares and nil-price options through personal and family trust-related structures. The update shows Palacio received 26,802 new ordinary shares, valued at $10,080 and issued at $0.3761 per share, in lieu of director’s fees for the quarter ending 31 December 2025, increasing his direct shareholding to 352,244 shares; the transaction underscores the company’s continued use of equity-based remuneration for board members, aligning director incentives more closely with shareholder interests.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has disclosed a change in the interests of non-executive director Douglas Lingard, in line with ASX requirements. Lingard increased his direct holding by 26,802 fully paid ordinary shares, taking his direct stake to 326,764 shares, alongside existing nil-price options and substantial indirect holdings through related entities. The additional shares were issued in lieu of director fees for the quarter ending 31 December 2025, highlighting the company’s ongoing practice of compensating directors partly in equity, which aligns their interests more closely with shareholders and modestly increases director ownership in the company.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has reported a change in the interests of non-executive director Damian Banks, who has increased his direct holding in the company. The additional 26,802 fully paid ordinary shares were issued in lieu of director fees for the quarter ending 31 December 2025, lifting Banks’ direct shareholding while his indirect holding via a superannuation fund remains unchanged; the move further aligns the director’s remuneration with shareholder outcomes but does not involve any on-market trading or changes to contractual interests.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has disclosed a change in the interests of non-executive director Douglas Flynn, who has both direct and indirect holdings in the company’s fully paid ordinary shares and options through various nominee and investment entities. Flynn’s direct holding increased by 53,604 fully paid ordinary shares, taking his direct shareholding to 160,573 shares, following the issue of new shares in lieu of non-executive director fees for the quarter ending 31 December 2025, a move that modestly strengthens director equity alignment without involving any on-market trading or closed-period clearances.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has applied to the ASX for quotation of 134,010 new ordinary fully paid shares issued under an employee incentive scheme. The additional securities, to be quoted from 23 December 2025, modestly expand the company’s quoted share capital and reflect ongoing use of equity-based remuneration, with limited immediate impact expected on existing shareholders given the relatively small size of the issue.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has notified the market that a total of 363,947 unlisted options over its shares have lapsed, following the failure or incapacity of the conditions attached to those securities to be satisfied. The cessation covers three series of nil‑exercise‑price options, with expiry dates in 2033, 2034 and 2035, and slightly reduces the company’s pool of potential future equity dilution, clarifying its issued capital structure for existing shareholders.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
IMEXHS Limited announced that CEO Dr. German Arango will sacrifice approximately 50% of his salary for six months in exchange for nil-price options, pending shareholder approval. This move aligns the CEO’s interests with shareholders and reflects his commitment to the company’s future, as the Long Term Incentive Plan has not yet vested options to executives.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.